Telaprevir increases cure rate in hepatitis C study

05/26/2010 | New York Times (tiered subscription model), The

Hepatitis C drug telaprevir reduced the virus to an undetectable level in 75% of clinical-trial patients who received the standard dose in combination with interferon and ribavirin, Vertex Pharmaceuticals reported. The study focused on patients with Genotype 1 hepatitis C who had not received treatment before the trial.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA